Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Monte Rosa Therapeutics Inc’s stock clocked out at $6.55, down -1.06% from its previous closing price of $6.62. In other words, the price has decreased by -$1.06 from its previous closing price. On the day, 0.66 million shares were traded. GLUE stock price reached its highest trading level at $6.65 during the session, while it also had its lowest trading level at $6.38.
Ratios:
To gain a deeper understanding of GLUE’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.39 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.96. For the most recent quarter (mrq), Quick Ratio is recorded 7.16 and its Current Ratio is at 7.16. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for the company, Wells Fargo on December 19, 2024, Downgraded its rating to Equal Weight and sets its target price to $11 from $14 previously.
On February 15, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $11.
Wells Fargo Upgraded its Equal Weight to Overweight on January 03, 2023, while the target price for the stock was maintained at $18.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 03 ’25 when Dunn Edmund sold 2,062 shares for $4.45 per share. The transaction valued at 9,174 led to the insider holds 23,732 shares of the business.
Leo Chandra P. bought 10,000 shares of GLUE for $58,383 on Mar 24 ’25. The Director now owns 10,000 shares after completing the transaction at $5.84 per share. On Oct 28 ’24, another insider, Versant Venture Capital VI, L., who serves as the 10% Owner of the company, sold 89,990 shares for $9.66 each. As a result, the insider received 869,240 and left with 2,007,948 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GLUE now has a Market Capitalization of 408846912 and an Enterprise Value of 155060736. As of this moment, Monte’s Price-to-Earnings (P/E) ratio for their current fiscal year is 19.09. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.27 while its Price-to-Book (P/B) ratio in mrq is 1.51. Its current Enterprise Value per Revenue stands at 0.871 whereas that against EBITDA is 6.656.
Stock Price History:
The Beta on a monthly basis for GLUE is 1.48, which has changed by 0.26692462 over the last 52 weeks, in comparison to a change of 0.15101504 over the same period for the S&P500. Over the past 52 weeks, GLUE has reached a high of $12.40, while it has fallen to a 52-week low of $3.50. The 50-Day Moving Average of the stock is 25.62%, while the 200-Day Moving Average is calculated to be 19.93%.
Shares Statistics:
It appears that GLUE traded 1.02M shares on average per day over the past three months and 4368930 shares per day over the past ten days. A total of 61.72M shares are outstanding, with a floating share count of 46.18M. Insiders hold about 25.23% of the company’s shares, while institutions hold 79.18% stake in the company. Shares short for GLUE as of 1756425600 were 8241602 with a Short Ratio of 8.07, compared to 1753920000 on 8701757. Therefore, it implies a Short% of Shares Outstanding of 8241602 and a Short% of Float of 17.669999999999998.
